Literature DB >> 1691537

Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells.

S M Metcalfe1, F M Richards.   

Abstract

Both cyclosporine and FK506 (FK) inhibit Con A-stimulated mouse spleen cells from entering the cell division cycle at the G0/G1 interface. Rapamycin, a fungal metabolite structurally related to FK, acts later and blocks progress through the cell division cycle at some point in G1. The effect of CsA, FK, and rapamycin drug combinations appeared additive, while certain concentrations of FK and rapamycin appeared to be antagonistic. The early blockade of lymphocyte activation caused by CsA and by FK was not due to altered membrane transport kinetics, nor to perturbation of the dynamic behavior of actin. However, both drugs showed the same specific effects on gene activation over a profile of genes encoding oncoproteins, putative transcription factors, cyclophilin, heat-shock proteins, IL-2, and IL-2-R. Of note was the drug-associated super-induction of krox-24 and reduced induction of krox-20. Both krox-24 and krox-20 encode proteins containing zinc-binding fingers, and are likely to regulate gene transcription, and this is the first report of gene control mechanisms being specifically affected by CsA and by FK.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691537

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

1.  Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation.

Authors:  S Miyamoto; B Safer
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

2.  Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.

Authors:  A Zeevi; M Woan; G Z Yao; R Venkataramanan; S Todo; T E Starzl; R J Duquesnoy
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits.

Authors:  G M Ferron; W J Jusko
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

5.  Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  Transplantation       Date:  1998-05-15       Impact factor: 4.939

Review 6.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1.

Authors:  L Brizuela; G Chrebet; K A Bostian; S A Parent
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

Review 8.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 9.  New immunosuppressive agents for pediatric transplantation.

Authors:  M Ferraresso; B D Kahan
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

10.  Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.

Authors:  Jaime A Yáñez; M Laird Forrest; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-29       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.